Selective inhibitors of XPO1 have been shown to possess antileukemic and proapoptotic activity in AML blasts by disrupting aberrant removal of tumor suppressor proteins from the nucleus, such as TP53 [7]. Here, XPO1 is linked to acute myeloid leukemia.